

Per year

2003 PPAR α reduces cholesterol esterification in macrophages.

G. CHINETTI, S. LESTAVEL, J.C. FRUCHART, V. CLAVEY, B. STAELS

Circulation Res., 2003, 92, 212-217.

Liver X receptors : new players in atherogenesis ?

V. BOCHER, L.J. MILLATT, J.C. FRUCHART, B. STAELS

Curr. Opin. Lipidol., 2003, 14, 137-143.

PPAR α and PPAR β/δ , but not PPAR γ , modulate the expression of genes involved in cardiac lipid metabolism.

A.J. GILDE, K.A. van der LEE, P.H. WILLEMSSEN, G. CHINETTI, F.R. van der LEIJ, G.J. van der Vusse, B. STAELS, M. van BILSEN

Circ. Res., 2003, 92, 518-524.

The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene.

O. BARBIER, L. VILLENEUVE, V. BOCHER, C. FONTAINE, I. PINEDA-TORRA, C. DUHEM, V. KOSYKH, J.C. FRUCHART, C. GUILLEMETTE, B. STAELS

J. Biol. Chem., 2003, 278, 13975-13983.

Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to PPAR α activators.

N. VU-DAC, P. GERVOIS, H. JAKEL, M. NOWAK, E. BAUGE, H. DEHONDT, B. STAELS, L.A. PENNACCHIO, E.M. RUBIN, J. FRUCHART-NAJIB, J.C. FRUCHART

J. Biol. Chem., 2003, 278, 17982-17985.

FXR induces the UGT2B4 enzyme in hepatocytes : a potential mechanism of negative feedback control of FXR activity.

O. BARBIER, I. PINEDA-TORRA, A. SIRVENT, T. CLAUDEL, C. BLANQUART, D. DURAN-SANDOVAL, F. KUIPERS, V. KOSYKH, J.C. FRUCHART, B. STAELS

Gastroenterology, 2003, 124, 1926-1940.

Farnesoid X Receptor agonists suppress hepatic apolipoprotein CIII expression.

T. CLAUDEL, Y. INOUE, O. BARBIER, D. DURAN-SANDOVAL, V. KOSYKH, J. FRUCHART, J.C. FRUCHART, F.J. GONZALEZ, B. STAELS
Gastroenterology, 2003, 125, 544-555.

PPAR α induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme.

O. BARBIER, D DURAN-SANDOVAL, I. PINEDA-TORRA, V. KOSYKH, J.C. FRUCHART, B. STAELS
J. Biol. Chem., 2003, 278, 32852-32860.

PPAR : regulation of transcriptional activities and roles in inflammation.

C. BLANQUART, O. BARBIER, J.C. FRUCHART, B. STAELS, C. GLINEUR
J. Steroid Biochem. Mol. Biol., 2003, 85, 267-273.

PPARs : new targets for the pharmacological modulation of macrophage gene expression and function.

G. CHINETTI, J.C. FRUCHART, B. STAELS
Curr. Opin. Lipidol., 2003, 14, 459-468.

The orphan nuclear receptor Rev-Erb α is a PPAR γ target gene and promotes PPAR γ -induced adipocyte differentiation.

C. FONTAINE, G. DUBOIS, Y. DUGUAY, T. HELLEDIE, N. VU-DAC, P. GERVOIS, F. SONCIN, S. MANDRUP, J.C. FRUCHART, J. FRUCHART-NAJIB, B. STAELS
J. Biol. Chem., 2003, 278, 37672-37680.

Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis.

A. TAILLEUX, G. TORPIER, H. MEZDOUR, J.C. FRUCHART, B. STAELS, C. FIEVET
Trends Pharmacol. Sci., 2003, 24, 530-534.

2004

Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPAR α , PPAR γ and LXR.

G. CHINETTI, C. ZAWADSKI, J.C. FRUCHART, B. STAELS

Biochem. Biophys. Res. Com., 2004, 314, 151-158.

Adipophilin enhances lipid accumulation and prevents lipid efflux from THP-1 macrophages : potential role in atherogenesis.

G. LARIGAUDERIE, C. FURMAN, M. JAYE, C. LASSELIN, C. COPIN, J.C. FRUCHART, G. CASTRO, M. ROUIS

Arterioscler. Thromb. Vasc. Biol., 2004, 24, 504-510.

Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the PPAR-alpha activator fenofibrate.

P. GERVOIS, R. KLEEMANN, A. PILON, F. PERCEVAULT, W. KOENIG, B. STAELS, T. KOOISTRA

J. Biol. Chem., 2004, 279, 16154-16160.

Glucose regulates the expression of the Farnesoid X Receptor in liver.

D. DURAN-SANDOVAL, G. MAUTINO, G. MARTIN, F. PERCEVAULT, O. BARBIER, J.C. FRUCHART, F. KUIPERS, B. STAELS

Diabetes, 2004, 53, 890-898.

Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages : potential relevance to atherosclerotic plaque stability.

C. FURMAN, C. COPIN, M. KANDOUSSI, R. DAVIDSON, M. MOREAU, F. McTAGGART, M.J. CHAPMAN, J.C. FRUCHART, M. ROUIS

Atherosclerosis, 2004, 174, 93-98.

PPARs and atherogenesis : regulators of gene expression in vascular cells.

N. MARX, H. DUEZ, J.C. FRUCHART, B. STAELS

Circ. Res., 2004, 94, 1168-1178.

The Farnesoid X Receptor induces very low density lipoprotein receptor gene expression.

A. SIRVENT, T. CLAUDEL, G. MARTIN, J. BROZEK, V. KOSYKH, R. DARTEIL, D.W. HUM, J.C. FRUCHART, B. STAELS

FEBS Letter, 2004, 566, 173-177.

Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5.

J. FRUCHART-NAJIB, E. BAUGE, L-S NICULESCU, T. PHAM, B. THOMAS, C. ROMMENS, Z. MAJD, B. BREWER, L.A. PENNACCHIO, J.C. FRUCHART

Biochem. Biophys. Res. Com., 2004, 319, 397-404.

Different ways to regulate the PPARalpha stability.

C. BLANQUART, R. MANSOURI, J.C. FRUCHART, B. STAELS, C. GLINEUR

Biochem. Biophys. Res. Com., 2004, 319, 663-670.

Thioredoxin reductase 1 is upregulated in atherosclerotic plaques : specific induction of the promoter in human macrophages by oxidized low-density lipoproteins.

C. FURMAN, A.K. RUNDLOF, G. LARIGAUDERIE, M. JAYE, G. BRICCA, C. COPIN, A.M. KANDOUSSI, J.C. FRUCHART, E.S.J. ARNER, M. ROUIS

Free Rad. Biol. Med., 2004, 37, 71-85.

Analysis of apolipoprotein A5, C3, and plasma triglyceride concentrations in genetically engineered mice.

N. BAROUKH, E. BAUGE, J. AKIYAMA, J. CHANG, V. AFZAL, J.C. FRUCHART, E.M. RUBIN, J.

FRUCHART-NAJIB, L.A. PENNACCHIO

Arterioscler. Thromb. Vasc. Biol., 2004, 24, 1297-1302.

Human free apolipoprotein A-I and artificial pre-beta-high-density lipoprotein inhibit eNOS activity and NO release.

O. BRIAND, F. MARTIN-NIZARD, M. DAVID-DUFILHO, I. SIX, S. LESTAVEL, A. BRUNET, J.C.

FRUCHART, G. TORPIER, R. BORDET, V. CLAVEY, P. DURIEZ

Biochim Biophys Acta, 2004, 1683, 69-77.

The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the PPARalpha.

C. BLANQUART, R. MANSOURI, R. PAUMELLE, J.C. FRUCHART, B. STAELS, C. GLINEUR

Mol. Endocrinol., 2004, 18, 1906-1918.

REDD2 gene is upregulated by modified LDL or hypoxia and mediates human macrophages cell death.

C. CUAZ-PEROLIN, C. FURMAN, G. LARIGAUDERIE, L. LEGEDZ, C. LASSELIN, C. COPIN, M.

JAYE, G. SEARFOSS, K.T. YU, N. DUVERGER, A. NEGRE-SALVAYRE, J.C. FRUCHART, M.

ROUIS

Arterioscler. Thromb. Vasc. Biol., 2004, Aug 12 (Epub ahead of print).

The LXR ligand T0901317 down-regulates apo A5 gene expression through activation of SREBP-1c

H. JAKEL, M. NOWAK, E. MOITROT, H. DEHONDT, D. HUM, L.A. PENNACCHIO, J. FRUCHART-

NAJIB, J.C. FRUCHART

J. Biol. Chem., 2004, Aug 17 (Epub ahead of print).

Per team

Bart Staels

PPAR α reduces cholesterol esterification in macrophages.

G. CHINETTI, S. LESTAVEL, J.C. FRUCHART, V. CLAVEY, B. STAELS
Circulation Res., 2003, 92, 212-217.

Liver X receptors : new players in atherogenesis ?

V. BOCHER, L.J. MILLATT, J.C. FRUCHART, B. STAELS
Curr. Opin. Lipidol., 2003, 14, 137-143.

PPAR α and PPAR β/δ , but not PPAR γ , modulate the expression of genes involved in cardiac lipid metabolism.

A.J. GILDE, K.A. van der LEE, P.H. WILLEMSSEN, G. CHINETTI, F.R. van der LEIJ, G.J. van der Vusse, B. STAELS, M. van BILSEN
Circ. Res., 2003, 92, 518-524.

The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene.

O. BARBIER, L. VILLENEUVE, V. BOCHER, C. FONTAINE, I. PINEDA-TORRA, C. DUHEM, V. KOSYKH, J.C. FRUCHART, C. GUILLEMETTE, B. STAELS
J. Biol. Chem., 2003, 278, 13975-13983.

Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to PPAR α activators.

N. VU-DAC, P. GERVOIS, H. JAKEL, M. NOWAK, E. BAUGE, H. DEHONDT, B. STAELS, L.A. PENNACCHIO, E.M. RUBIN, J. FRUCHART-NAJIB, J.C. FRUCHART
J. Biol. Chem., 2003, 278, 17982-17985.

FXR induces the UGT2B4 enzyme in hepatocytes : a potential mechanism of negative feedback control of FXR activity.

O. BARBIER, I. PINEDA-TORRA, A. SIRVENT, T. CLAUDEL, C. BLANQUART, D. DURAN-SANDOVAL, F. KUIPERS, V. KOSYKH, J.C. FRUCHART, B. STAELS
Gastroenterology, 2003, 124, 1926-1940.

Farnesoid X Receptor agonists suppress hepatic apolipoprotein CIII expression.

T. CLAUDEL, Y. INOUE, O. BARBIER, D. DURAN-SANDOVAL, V. KOSYKH, J. FRUCHART, J.C. FRUCHART, F.J. GONZALEZ, B. STAELS
Gastroenterology, 2003, 125, 544-555.

PPAR α induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme.

O. BARBIER, D. DURAN-SANDOVAL, I. PINEDA-TORRA, V. KOSYKH, J.C. FRUCHART, B. STAELS
J. Biol. Chem., 2003, 278, 32852-32860.

PPAR : regulation of transcriptional activities and roles in inflammation.

C. BLANQUART, O. BARBIER, J.C. FRUCHART, B. STAELS, C. GLINEUR
J. Steroid Biochem. Mol. Biol., 2003, 85, 267-273.

PPARs : new targets for the pharmacological modulation of macrophage gene expression and function.

G. CHINETTI, J.C. FRUCHART, B. STAELS
Curr. Opin. Lipidol., 2003, 14, 459-468.

The orphan nuclear receptor Rev-Erb α is a PPAR γ target gene and promotes PPAR γ -induced adipocyte differentiation.

C. FONTAINE, G. DUBOIS, Y. DUGUAY, T. HELLEDIE, N. VU-DAC, P. GERVOIS, F. SONCIN, S. MANDRUP, J.C. FRUCHART, J. FRUCHART-NAJIB, B. STAELS
J. Biol. Chem., 2003, 278, 37672-37680.

Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis.

A. TAILLEUX, G. TORPIER, H. MEZDOUR, J.C. FRUCHART, B. STAELS, C. FIEVET
Trends Pharmacol. Sci., 2003, 24, 530-534.

Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPAR α , PPAR γ and LXR.

G. CHINETTI, C. ZAWADSKI, J.C. FRUCHART, B. STAELS
Biochem. Biophys. Res. Com., 2004, 314, 151-158.

Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the PPAR-alpha activator fenofibrate.

P. GERVOIS, R. KLEEMANN, A. PILON, F. PERCEVAULT, W. KOENIG, B. STAELS, T. KOOISTRA
J. Biol. Chem., 2004, 279, 16154-16160.

Glucose regulates the expression of the Farnesoid X Receptor in liver.

D. DURAN-SANDOVAL, G. MAUTINO, G. MARTIN, F. PERCEVAULT, O. BARBIER, J.C. FRUCHART, F. KUIPERS, B. STAELS
Diabetes, 2004, 53, 890-898.

PPARs and atherogenesis : regulators of gene expression in vascular cells.

N. MARX, H. DUEZ, J.C. FRUCHART, B. STAELS
Circ. Res., 2004, 94, 1168-1178.

The Farnesoid X Receptor induces very low density lipoprotein receptor gene expression.

A. SIRVENT, T. CLAUDEL, G. MARTIN, J. BROZEK, V. KOSYKH, R. DARTEIL, D.W. HUM, J.C. FRUCHART, B. STAELS
FEBS Letter, 2004, 566, 173-177.

Different ways to regulate the PPARalpha stability.

C. BLANQUART, R. MANSOURI, J.C. FRUCHART, B. STAELS, C. GLINEUR
Biochem. Biophys. Res. Com., 2004, 319, 663-670.

The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the PPARalpha.

C. BLANQUART, R. MANSOURI, R. PAUMELLE, J.C. FRUCHART, B. STAELS, C. GLINEUR
Mol. Endocrinol., 2004, 18, 1906-1918.

Mustapha Rouis

Adipophilin enhances lipid accumulation and prevents lipid efflux from THP-1 macrophages : potential role in atherogenesis.

G. LARIGAUDERIE, C. FURMAN, M. JAYE, C. LASSELIN, C. COPIN, J.C. FRUCHART, G. CASTRO, M. ROUIS
Arterioscler. Thromb. Vasc. Biol., 2004, 24, 504-510.

Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages : potential relevance to atherosclerotic plaque stability.

C. FURMAN, C. COPIN, M. KANDOUSSI, R. DAVIDSON, M. MOREAU, F. McTAGGART, M.J. CHAPMAN, J.C. FRUCHART, M. ROUIS
Atherosclerosis, 2004, 174, 93-98.

Thioredoxin reductase 1 is upregulated in atherosclerotic plaques : specific induction of the promoter in human macrophages by oxidized low-density lipoproteins.
C. FURMAN, A.K. RUNDLOF, G. LARIGAUDERIE, M. JAYE, G. BRICCA, C. COPIN, A.M. KANDOUSSI, J.C. FRUCHART, E.S.J. ARNER, M. ROUIS
Free Rad. Biol. Med., 2004, 37, 71-85.

REDD2 gene is upregulated by modified LDL or hypoxia and mediates human macrophages cell death.

C. CUAZ-PEROLIN, C. FURMAN, G. LARIGAUDERIE, L. LEGEDZ, C. LASSELIN, C. COPIN, M. JAYE, G. SEARFOSS, K.T. YU, N. DUVERGER, A. NEGRE-SALVAYRE, J.C. FRUCHART, M. ROUIS
Arterioscler. Thromb. Vasc. Biol., 2004, Aug 12 (Epub ahead of print).

Jamila Fruchart

Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to PPAR α activators.

N. VU-DAC, P. GERVOIS, H. JAKEL, M. NOWAK, E. BAUGE, H. DEHONDT, B. STAELS, L.A. PENNACCHIO, E.M. RUBIN, J. FRUCHART-NAJIB, J.C. FRUCHART
J. Biol. Chem., 2003, 278, 17982-17985.

Farnesoid X Receptor agonists suppress hepatic apolipoprotein CIII expression.

T. CLAUDEL, Y. INOUE, O. BARBIER, D. DURAN-SANDOVAL, V. KOSYKH, J. FRUCHART, J.C. FRUCHART, F.J. GONZALEZ, B. STAELS
Gastroenterology, 2003, 125, 544-555.

The orphan nuclear receptor Rev-Erb α is a PPAR γ target gene and promotes PPAR γ -induced adipocyte differentiation.

C. FONTAINE, G. DUBOIS, Y. DUGUAY, T. HELLEDIE, N. VU-DAC, P. GERVOIS, F. SONCIN, S. MANDRUP, J.C. FRUCHART, J. FRUCHART-NAJIB, B. STAELS
J. Biol. Chem., 2003, 278, 37672-37680.

Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5.

J. FRUCHART-NAJIB, E. BAUGE, L-S NICULESCU, T. PHAM, B. THOMAS, C. ROMMENS, Z. MAJD, B. BREWER, L.A. PENNACCHIO, J.C. FRUCHART
Biochem. Biophys. Res. Com., 2004, 319, 397-404.

Analysis of apolipoprotein A5, C3, and plasma triglyceride concentrations in genetically engineered mice.

N. BAROUKH, E. BAUGE, J. AKIYAMA, J. CHANG, V. AFZAL, J.C. FRUCHART, E.M. RUBIN, J. FRUCHART-NAJIB, L.A. PENNACCHIO

Arterioscler. Thromb. Vasc. Biol., 2004, 24, 1297-1302.

The LXR ligand T0901317 down-regulates apo A5 gene expression through activation of SREBP-1c
H. JAKEL, M. NOWAK, E. MOITROT, H. DEHONDT, D. HUM, L.A. PENNACCHIO, J. FRUCHART-
NAJIB, J.C. FRUCHART

J. Biol. Chem., 2004, Aug 17 (Epub ahead of print).

Autre

Human free apolipoprotein A-I and artificial pre-beta-high-density lipoprotein inhibit eNOS activity and NO release.

O. BRIAND, F. MARTIN-NIZARD, M. DAVID-DUFILHO, I. SIX, S. LESTAVEL, A. BRUNET, J.C. FRUCHART,
G. TORPIER, R. BORDET, V. CLAVEY, P. DURIEZ

Biochim Biophys Acta, 2004, 1683, 69-77.